Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by G. J. Poston
Based on 3 articles published since 2008
||||

Between 2008 and 2019, G. Poston wrote the following 3 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). 2012

Ramage, John K / Ahmed, A / Ardill, J / Bax, N / Breen, D J / Caplin, M E / Corrie, P / Davar, J / Davies, A H / Lewington, V / Meyer, T / Newell-Price, J / Poston, G / Reed, N / Rockall, A / Steward, W / Thakker, R V / Toubanakis, C / Valle, J / Verbeke, C / Grossman, A B / Anonymous3000709. ·Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke RG24 9NA, UK. john.ramage@bnhft.nhs.uk ·Gut · Pubmed #22052063.

ABSTRACT: These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology, the Society for Endocrinology, the Association of Surgeons of Great Britain and Ireland (and its Surgical Specialty Associations), the British Society of Gastrointestinal and Abdominal Radiology and others. The authorship represents leaders of the various groups in the UK and Ireland Neuroendocrine Tumour Society, but a large amount of work has been carried out by other specialists, many of whom attended a guidelines conference in May 2009. We have attempted to represent this work in the acknowledgements section. Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments. However, there remain few randomised trials in the field and the disease is uncommon, hence all evidence must be considered weak in comparison with other more common cancers.

2 Article Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. 2016

de Leede, E M / Sibinga Mulder, B G / Bastiaannet, E / Poston, G J / Sahora, K / Van Eycken, E / Valerianova, Z / Mortensen, M B / Dralle, H / Primic-Žakelj, M / Borràs, J M / Gasslander, T / Ryzhov, A / Lemmens, V E / Mieog, J S D / Boelens, P G / van de Velde, C J H / Bonsing, B A. ·Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. · Department of Surgery, University Hospital Aintree, Liverpool, United Kingdom. · Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna/ABCSG Pancreatic Cancer Registry, Austria. · Belgian Cancer Registry, Brussels, Belgium. · Bulgarian National Cancer Registry/National Oncological Hospital, Sofia, Bulgaria. · Department of Surgery, Odense University Hospital/Danish Pancreas Cancer Group, Denmark. · Department of Surgery, University of Halle-Wittenberg/Pancreatic Cancer Register, Halle, Germany. · Epidemiology and Cancer Registry/Institute of Oncology, Ljubljana, Slovenia. · Department of Clinical Sciences, University of Barcelona, Barcelona, Spain. · Department of Surgery, Linköping University/Swedish Registry for Pancreatic Tumors, Sweden. · National Cancer Registry of Ukraine/National Institute of Cancer, Kiev, Ukraine. · Department of Research, Netherlands Cancer Registry/Comprehensive Cancer Centre The Netherlands (IKNL), Eindhoven, The Netherlands. · Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. Electronic address: c.j.h.van_de_velde@lumc.nl. ·Eur J Surg Oncol · Pubmed #27061790.

ABSTRACT: BACKGROUND: Quality assurance of cancer care is of utmost importance to detect and avoid under and over treatment. Most cancer data are collected by different procedures in different countries, and are poorly comparable at an international level. EURECCA, acronym for European Registration of Cancer Care, is a platform aiming to harmonize cancer data collection and improve cancer care by feedback. After the prior launch of the projects on colorectal, breast and upper GI cancer, EURECCA's newest project is collecting data on pancreatic cancer in several European countries. METHODS: National cancer registries, as well as specific pancreatic cancer audits/registries, were invited to participate in EURECCA Pancreas. Participating countries were requested to share an overview of their collected data items. Of the received datasets, a shared items list was made which creates insight in similarities between different national registries and will enable data comparison on a larger scale. Additionally, first data was requested from the participating countries. RESULTS: Over 24 countries have been approached and 11 confirmed participation: Austria, Belgium, Bulgaria, Denmark, Germany, The Netherlands, Slovenia, Spain, Sweden, Ukraine and United Kingdom. The number of collected data items varied between 16 and 285. This led to a shared items list of 25 variables divided into five categories: patient characteristics, preoperative diagnostics, treatment, staging and survival. Eight countries shared their first data. CONCLUSIONS: A list of 25 shared items on pancreatic cancer coming from eleven participating registries was created, providing a basis for future prospective data collection in pancreatic cancer treatment internationally.

3 Article Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. 2013

Vinjamuri, S / Gilbert, T M / Banks, M / McKane, G / Maltby, P / Poston, G / Weissman, H / Palmer, D H / Vora, J / Pritchard, D M / Cuthbertson, D J. ·Department of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, UK, L7 8XP. ·Br J Cancer · Pubmed #23492685.

ABSTRACT: BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an established treatment for patients with metastatic neuroendocrine tumours (NETs), although which factors are associated with an improved overall survival (OS) remains unclear. The primary aim of this study is to determine to what extent a radiological response to (90)Y-DOTATOC/(90)Y-DOTATATE PRRT is associated with an improved OS. The association of biochemical and clinical response to OS were assessed as secondary outcome measures. METHODS: A retrospective analysis was conducted on 57 patients: radiological response was classified using RECIST criteria, biochemical response was classified using WHO criteria and clinical response was assessed subjectively. Responses were recorded as positive response (PR), stable disease (SD) or progressive disease (PD), and survival analysed. RESULTS: Radiological response was achieved in 71.5% (24.5% PR, 47% SD) and was associated with a greater OS (51 and 56 months, respectively), compared with PD (18 months). A biochemical or clinical response post PRRT were not associated with a statistically significant improvement in OS. However, when combined with radiological response a survival benefit was observed according to the number of outcomes (radiological, biochemical, clinical), in which a response was observed. Mild haematological toxicity was common, renal toxicity was rare. CONCLUSION: In patients with progressive metastatic NETs receiving (90)Y-DOTATOC/(90)Y-DOTATATE PRRT, a radiological response with either a PR or a SD post therapy confers a significant OS benefit.